Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

53 trials with published results (25%)

Research Maturity

151 completed trials (70% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.3%

5 terminated out of 215 trials

Success Rate

96.8%

+10.2% vs benchmark

Late-Stage Pipeline

28%

61 trials in Phase 3/4

Results Transparency

35%

53 of 151 completed with results

Key Signals

53 with results97% success

Data Visualizations

Phase Distribution

192Total
Not Applicable (66)
Early P 1 (2)
P 1 (18)
P 2 (45)
P 3 (45)
P 4 (16)

Trial Status

Completed151
Unknown28
Recruiting12
Not Yet Recruiting9
Terminated5
Withdrawn4

Trial Success Rate

96.8%

Benchmark: 86.5%

Based on 151 completed trials

Clinical Trials (215)

Showing 20 of 20 trials
NCT07238699Not ApplicableCompletedPrimary

An Evaluation of the Safety and Tolerability of Ocular Lubricants

NCT07025811Phase 4CompletedPrimary

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

NCT07128628Phase 2CompletedPrimary

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

NCT07284381Phase 3Active Not RecruitingPrimary

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07264517Phase 2CompletedPrimary

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

NCT07540884Not ApplicableRecruitingPrimary

Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops

NCT06903611Phase 3Not Yet RecruitingPrimary

Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye

NCT05865457Not ApplicableRecruitingPrimary

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease

NCT05865379Not ApplicableRecruitingPrimary

Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease

NCT07623382Early Phase 1RecruitingPrimary

Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease

NCT06483750Not ApplicableCompletedPrimary

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

NCT05514041Phase 4CompletedPrimary

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05586152Phase 1CompletedPrimary

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

NCT06544694Phase 3CompletedPrimary

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT07140380Phase 2CompletedPrimary

Phase 2b Controlled Study

NCT06660290Phase 3CompletedPrimary

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT07469865Not ApplicableCompletedPrimary

Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)

NCT07457021Not Yet RecruitingPrimary

A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)

NCT06444516Not ApplicableCompletedPrimary

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

NCT06244316Phase 2CompletedPrimary

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Scroll to load more

Research Network

Activity Timeline